OneSource Specialty Pharma Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/qbzh1sm0ch9dmsstlx2md0ob.pdf

Key Takeaways


The Semaglutide Opportunity: Demand Signals vs Market Noise

Neeraj Sharma: "I mean, our customers are the who's who of the generic industry. And I think there is nobody better than them to really forecast the market. So, we just make sure that our customer demand"

M&A: Poland and Baroda


Capacity Expansion: Pulled Forward, Largely Spoken For

Neeraj Sharma: "we would be having now this capacity, all capacity up and qualified by end of calendar 2026."

Business Segments: DDC Leads, Injectables and Softgels Steady


Pipeline Beyond Semaglutide


Regulatory and Operational Resilience


Guidance & Commitments

CommitmentSpecificsTimeline
Organic revenue target$400 mn revenue organicallyBy FY28
Combined revenue target (if M&A closes)In excess of $500 mn revenue, slightly in excess of $200 mn EBITDAPost-transaction close (12–18 month NCLT process)
Phase 2 capacity qualification20 crore cartridges up and qualifiedEnd of calendar 2026 (accelerated by one year)
Debt-to-EBITDABelow 1.5x, with possible temporary overshoot due to accelerated capexDuring FY26
Semaglutide commercial suppliesRevenue from commercial supplies begins, subject to customer approvalsH2 FY26
Liraglutide and Teriparatide launchBoth products manufactured; launch dependent on customer prioritiesH1 FY26
Ertapenem lyophilised form approval (Baroda)US approval expectedNext couple of months
Poland and Baroda transaction closeNCLT process including SEBI pre-approval, NCLT filing, shareholder approval12–18 months

Key Metrics

MetricQ1 FY26
Revenue₹327.3 cr, +12% YoY
EBITDA₹88.5 cr, +37% YoY
EBITDA margin27%, up 500 bps YoY
Adjusted PAT₹37.1 cr, compared to negative PAT in prior-year quarter
Adjusted EPS (fully diluted)₹3.2 per share
Organic revenue target$400 million by FY28
Capex plan$100 million total, Phase 2 accelerated to complete by end of CY2026
Current DDC capacity4 crore units, large part contracted under take-or-pay for early launch markets
DDC molecules in development10 molecules, of which 3 are GLPs
Credit ratingUpgraded to A family
Target debt-to-EBITDABelow 1.5x, may temporarily exceed in some quarters during capex
Inorganic assets revenue (Poland & Baroda)~$65 million in FY26, contracted to deliver at least $100 million in FY27
Inorganic assets EBITDA margin36% to 40% range
Pro forma combined revenue targetIn excess of $500 million, with EBITDA in excess of $200 million